PL372226A1 - Pochodne pirydynoamidu jako inhibitory monoaminooksydazy (MAO-B) - Google Patents

Pochodne pirydynoamidu jako inhibitory monoaminooksydazy (MAO-B)

Info

Publication number
PL372226A1
PL372226A1 PL03372226A PL37222603A PL372226A1 PL 372226 A1 PL372226 A1 PL 372226A1 PL 03372226 A PL03372226 A PL 03372226A PL 37222603 A PL37222603 A PL 37222603A PL 372226 A1 PL372226 A1 PL 372226A1
Authority
PL
Poland
Prior art keywords
pyridineamido
mao
inhibitors
derivatives
monoamine oxidase
Prior art date
Application number
PL03372226A
Other languages
English (en)
Inventor
Andrea Cesura
Sarmiento Rosa Maria Rodriguez
Andrew William Thomas
Rene Wyler
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL372226A1 publication Critical patent/PL372226A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL03372226A 2002-02-04 2003-01-27 Pochodne pirydynoamidu jako inhibitory monoaminooksydazy (MAO-B) PL372226A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02001969 2002-02-04

Publications (1)

Publication Number Publication Date
PL372226A1 true PL372226A1 (pl) 2005-07-11

Family

ID=27675593

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372226A PL372226A1 (pl) 2002-02-04 2003-01-27 Pochodne pirydynoamidu jako inhibitory monoaminooksydazy (MAO-B)

Country Status (13)

Country Link
US (1) US6667327B2 (pl)
EP (1) EP1474394A1 (pl)
JP (1) JP4217159B2 (pl)
KR (1) KR100621297B1 (pl)
CN (1) CN1261414C (pl)
AR (1) AR038342A1 (pl)
AU (1) AU2003205677B2 (pl)
BR (1) BR0307444A (pl)
CA (1) CA2473459A1 (pl)
MX (1) MXPA04007501A (pl)
PL (1) PL372226A1 (pl)
RU (1) RU2309950C2 (pl)
WO (1) WO2003066596A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004283452A1 (en) * 2003-10-23 2005-05-06 F. Hoffmann-La Roche Ag Benzazepine derivatives as MAO-B inhibitors
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
WO2006138475A2 (en) * 2005-06-16 2006-12-28 Jenrin Discovery Mao-b inhibitors useful for treating obesity
RU2012116124A (ru) * 2009-09-21 2013-10-27 Вандербилт Юниверсити О-БЕНЗИЛ НИКОТИНАМИДНЫЕ АНАЛОГИ КАК ПОЗИТИВНЫЕ АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ mGluR5
IT1404729B1 (it) * 2011-01-27 2013-11-29 Univ Pisa Inibitori altamente selettivi dell'attivita' di adams
KR101746060B1 (ko) 2015-09-18 2017-06-12 한국과학기술연구원 항비만 치료용 가역적 마오비 저해제
CN105601563B (zh) * 2015-12-17 2018-05-08 浙江工业大学 6-氯-n-(4-(6-氯烟酰胺)苄基)烟酰胺及其制备和应用
CN108912029B (zh) * 2017-08-25 2021-10-01 广东东阳光药业有限公司 含氮杂环酰胺衍生物及其用途
CN107903289B (zh) * 2017-11-08 2020-07-31 中国科学院烟台海岸带研究所 一种基于花菁的有机化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1368314A1 (ru) * 1984-02-22 1988-01-23 Научно-исследовательский институт фармакологии АМН СССР @ -Никотиноиламинокислоты, обладающие противогипоксической и антиамнестической активностью
CA1261335A (en) 1984-08-29 1989-09-26 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Ethylenediamine monoamide derivatives
SU1560052A3 (ru) * 1985-09-24 1990-04-23 Шеринг Аг (Фирма) Гербицидное средство
JPH02142774A (ja) 1988-11-25 1990-05-31 Mitsui Toatsu Chem Inc 2−(4−置換フェニル)イミダゾリノン類、その製造法、およびそれらを有効成分として含有する除草剤
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
CA2090857A1 (en) 1990-09-17 1992-03-18 David A. Clark 5-trifluoroacylamino-2-aryloxazoles 2-aryl-5-trifluoroacylaminooxazoles
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
BR9812240A (pt) 1997-09-19 2000-07-18 American Cyanamid Co Proteìna g alterada ou polipeptìdeo do rsv, uso da mesma, molécula de ácido nucleico codificando uma proteìna g alterada ou um polipeptìdeo do rsv, construção do ácido nucleico, célula hospedeira recombinante, processos de produção de uma proteìna g alterada ou polipeptìdeo do rsv composição imunogênica, de indução de uma resposta imune em um vertebrado, de inibir a indução do aumento da doença após a vacinação e subsequente infecção de um vertebrado com o rsv e de imunização de um vertebrado contra o rsv, composição de vacina, vacina, e, composição imunogênica
EP1032377B1 (en) 1997-11-21 2010-11-17 Purdue Neuroscience Company Substituted 2-aminoacetamides and the use thereof
GB9727521D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Substituted 2-benzylamino-2-phenyl-acetamide compounds
ATE359263T1 (de) 1998-04-20 2007-05-15 Ortho Mcneil Pharm Inc Substitutierte aminosaeuren als erythropoietin- mimetica
US6294694B1 (en) 1999-06-04 2001-09-25 Wisconsin Alumni Research Foundation Matrix metalloproteinase inhibitors and method of using same
DE19952146A1 (de) 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6306911B1 (en) 2000-02-07 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as neutral sphingomyelinase inhibitors

Also Published As

Publication number Publication date
CN1628102A (zh) 2005-06-15
EP1474394A1 (en) 2004-11-10
AR038342A1 (es) 2005-01-12
BR0307444A (pt) 2004-12-28
WO2003066596A1 (en) 2003-08-14
JP2005528339A (ja) 2005-09-22
AU2003205677A1 (en) 2003-09-02
KR100621297B1 (ko) 2006-09-13
CA2473459A1 (en) 2003-08-14
AU2003205677B2 (en) 2008-04-24
MXPA04007501A (es) 2004-11-10
US6667327B2 (en) 2003-12-23
US20030158235A1 (en) 2003-08-21
JP4217159B2 (ja) 2009-01-28
RU2309950C2 (ru) 2007-11-10
RU2004126861A (ru) 2005-05-27
KR20040082407A (ko) 2004-09-24
CN1261414C (zh) 2006-06-28

Similar Documents

Publication Publication Date Title
EP1551801A4 (en) NOVEL GAMMA-LACTAMES AS INHIBITORS OF BETA-SECRETASE
EP1549316A4 (en) HAMMER OF TFGbeta
IL169691A0 (en) Malonamide derivatives as gamma-secretase inhibitors
IL236013A (en) Edamantyl acetamide derivatives as 11-beta-hydroxysteroid dehydrogenase enzyme inhibitors
SI1492785T1 (sl) 2-hidroksi-3-heteroarilindolni derivati kot inhibitorji GSK3
AP1967A (en) Thiazolidinone compounds as inhibitors of Hyak3
AU2003261434A8 (en) Iminothiazolidinones as inhibitors of hcv replication
PL1635840T3 (pl) Tiofenopirymidynony jako inhibitory dehydrogenazy 17-beta-hydroksysteroidowej
HRP20041087A2 (en) N-acylaminobenzene derivatives as selective monoamine oxidase b inhibitors
PL374279A1 (pl) Nitrooksypochodne inhibitorów cyklooksygenazy-2
PL371439A1 (pl) Pochodne ftalimidu jako inhibitory monoaminoksydazy B
AU2003290735A1 (en) Inhibitors of monoamine uptake
PL372226A1 (pl) Pochodne pirydynoamidu jako inhibitory monoaminooksydazy (MAO-B)
AU2003230392A1 (en) Beta-secretase inhibitors
ZA200409691B (en) Heterotricyclyl 6-alkylidene-penems as ß-lactamase inhibitors
PL373523A1 (pl) Indol-2-ony jako selektywne inhibitory cyklooksygenazy-2
AU2003216848A1 (en) Deracemisation of amines
IL157779A0 (en) Inhibitor of monoamine uptake
AU2003242559A1 (en) Alkylaminosiloxanes as corrosion inhibitors
AU2003228701A1 (en) Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases
SI1487802T1 (sl) 2,3-diaril-pirazolidinski derivati kot inhibitorji encimov, ki razgrajujejo nevrotenzin
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
EP1924275A4 (en) INHIBITORS CONTAINING THIO COMPOUND OF AMINOPEPTIDASE P, THEIR COMPOSITIONS AND METHOD OF USE
AU2003250467A1 (en) Diaryl compounds as monoamine reuptake inhibitors
GB0314414D0 (en) Inhibitors of monoamine uptake

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)